Global Plasma Protein Therapeutic Market is expected to grow at a CAGR of 6.12% during the forecast period from 2019-2025

As per the report published by Fior Markets, the global plasma protein therapeutic market is expected to grow from USD 24.12 Billion in 2017 to USD 39.91 Billion by 2025 at a CAGR of 6.12%during the forecast period from 2018-2025. NorthAmericais expected to dominate themarket during the forecast period. Presence of large patient base and availability of well-developed infrastructure for storing and maintaining high-quality source plasma are major factors driving the growth of the market.

Global Plasma Protein Therapeutic Market byProduct (Immunoglobulin, Albumin, Plasma Derived Factor Viii, Others), Application, Region" and Global Forecast 2018-2025.

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/376059/request-sample

Key players operating in the market include includeOctapharma AG, CSL Behring LLC, Grifols S.A., Bayer AG, Shire Plc, Kedrion S.P.A., Amgen Inc., Eli Lilly and Company, Abbott, Biogen Inc., F. Hoffmann-La Roche, Merck & Co., Novo Nordisk, Pfizer Inc., SanofiS.Aamong others.Manufacturers are focusing on collaborations for expansion of their product portfolio and conducting clinical trials to increase their market share. For instance,in June 2016, Shire Plc acquired Baxalta. Through this deal, Shire acquired Baxalta's product portfolio and a strong pipeline for the treatment of rare diseases. Moreover, in August 2018, Grifols S.A. acquired 24 plasma donor centers in the U.S. These are operated by Biotest AG.

Product segment includes albumin, Immunoglobulins (IG), plasma-derived factor VIII, and others. The immunoglobulin segment is dominating the marketand is anticipated to grow with the highest CAGR of 8.42% over the forecast period. Approval of biologics for multiple indications, easy administration process and less treatment cost are fuelling the growth of the market.Applicationsegment is divided into hemophilia, primary immunodeficiency diseases (PID), idiopathic thrombocytopenic purpura (ITP), and others. The Primary immunodeficiency segment is dominating and was valued around USD 11.33 billion in 2017. More than 6.0 million individuals are living with a PID worldwide. Increasing development of clinical applications for immunoglobulins and approval of SCIGs are driving the growth of the segment.

ACCESS FULL REPORT:https://www.fiormarkets.com/report/global-plasma-protein-therapeutic-market-by-product-immunoglobulin-376059.html

Technological advancements, rise in geriatric population,favourable reimbursement policies, and improved standard of living have led to increased life expectancy are driving the market. In addition, advancements in recombinant therapeutic drugs are expected to strengthen the recombinant therapeutic antibodies and proteins market.Changing regulatory requirements and lack of skilled professionals may restrict thegrowth of the market. However, governments supporting research and development of novel products due to rapid advancements in biomedical science and technology to address unmet medical needs are driving the market in future.

Customization of the Report:This report can be customized to meet the client's requirements. Please connect with our sales team (sales@fiormarkets.com), who will ensure that you get a report that suits your needs.

Contact Us

Mark Stone
Sales Manager
Office-102, Sanskriti Aspirations
Baner Road, Pune,
MH 411045
India
Phone: (201) 465-4211
Email: sales@fiormarkets.com
Web: www.fiormarkets.com

About Us:

Fior Markets is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients' objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports. We sell market research reports obtained from major publishers from various industries, in which a comprehensive overview of the market is provided along with statistical forecasts, strategic recommendations, detailed segmentation, current market scenario, competitive landscape and key trends.

This release was published on openPR.